Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ISIS Pharmaceuticals, Inc. : Wall Street Fundamentals Releases New In-Depth Stock Reports on ISIS, KERX, KIOR and MACK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/15/2013 | 02:45pm CET

Investors are set to receive important information regarding the state of the economy this coming week as reports on inflation and retail sales are to be released and a number of industry bellwethers such as General Electric, Intel, Microsoft and the remaining big banks are also set to report earnings. The Russell 2000 Index closed at a new record high for the third consecutive trading day, the index has gained roughly 22.0 percent year-to-date outpacing both the Dow Jones and the S&P 500. "It's bullish that the Russell 2000 has reversed its downtrend off the May 22 highs and breaking out to new highs," said Craig Johnson, a Piper Jaffray managing director and senior technical research analyst "And when we get an index as broad as the Russell 2000 breaking out to new highs, that suggests that the internals of the market is very strong and we have a lot of stocks that are participating in this move." Here is how some companies in the Russell 2000 Index reacted Friday:

ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares traded in the range of $32.29 to $33.94 Friday before settling to close at $33.72, an increase of 3.12 percent. The stock appears to have some support at the $32.06 and $30.46 levels. Shares of ISIS Pharmaceuticals have gained approximately 220.0 percent in 2013.

More information on ISIS Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ISIS

Keryx Biopharmaceuticals (NASDAQ: KERX) shares traded in the range of $7.93 to $8.15 Friday before settling to close at $8.11, an increase of 1.76 percent. The stock appears to be facing some resistance at the $8.35 and $8.75 levels with some support at $7.69. Shares of Keryx Biopharmaceuticals have gained approximately 210.0 percent in 2013.

More information on Keryx Biopharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/KERX

KiOR Inc. (NASDAQ: KIOR) shares traded in the range of $4.33 to $4.45 Friday before settling to close at $4.37, an increase of 0.23 percent. The stock appears to be facing some resistance at the $4.52 and $4.64 levels with some support at $4.31. Shares of KiOR have fallen approximately 31.8 percent in 2013.

More information on KiOR and access to the free equity report can be found at:
www.WallStreetFundamentals.com/KIOR

Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares traded in the range of $4.98 to $5.19 Friday before settling to close at $5.08, an increase of 0.99 percent. The stock appears to be facing some resistance at the $5.32 and $5.65 levels with some support at $5.05. Shares of Merrimack Pharmaceuticals have fallen approximately 16.5 percent in 2013.

More information on Merrimack Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/MACK

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
12/01 OTONOMY : Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer
11/17 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Third Quart..
11/17 IONIS PHARMACEUTICALS : 1,000 Shares of Stock are Sold by Ionis Pharmaceuticals ..
11/15 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals Reports Positive Clinical Data from..
11/10 IONIS PHARMACEUTICALS : Reports Positive Phase 2 Data for IONIS-FXI Rx in Patien..
11/09 IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
11/09 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Reports Financial Resul..
11/09 IONIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
11/09 IONIS PHARMACEUTICALS : misses Street 3Q forecasts
11/08 IONIS PHARMACEUTICALS INC. : (IONS) is Trading Lower on Unusual Volume for Novem..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2016 275 M
EBIT 2016 -101 M
Net income 2016 -130 M
Finance 2016 40,6 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 18,8x
EV / Sales 2017 15,5x
Capitalization 5 212 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 43,6 $
Spread / Average Target 1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 212
INCYTE CORPORATION-7.86%19 219
QUINTILES IMS HOLDINGS..6.32%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.48.64%9 442
LONZA GROUP AG11.34%9 247
More Results